EP4366686A1

EP4366686A1 - Anti-sun cosmetic composition containing mycosporine-like amino acids

Info

Publication number: EP4366686A1
Application number: EP22751136.7A
Authority: EP
Inventors: Jean-Noël THOREL
Original assignee: Naos Institute of Life Science SAS
Current assignee: Naos Institute of Life Science SAS
Priority date: 2021-07-08
Filing date: 2022-07-07
Publication date: 2024-05-15
Also published as: WO2023281224A1; CA3222853A1; KR20240032736A; CN117529303A; FR3124945A1; BR112023025482A2

Abstract

The present invention relates to a composition and to the use thereof for protecting against ultraviolet solar radiation. In particular, the invention relates to a composition comprising: - at least one mycosporine-like amino acid, referred to as "MAA"; - at least two organic screening agents chosen from UVB organic screening agents and/or broad-spectrum organic screening agents which absorb both in the UVB range and the UVA range; - at least one UVA organic screening agent.

Description

SUN COSMETIC COMPOSITION CONTAINING AMINO ACIDS ANALOGS OF MYCOSPORINE Field of the invention The present invention relates to a composition, in particular a cosmetic or dermatological composition, advantageously sunscreen comprising amino acids analogs of mycosporin and sun filters, as well as its use to protect the skin from ultraviolet radiation. PRIOR STATE OF THE ART Ultraviolet (UV) radiation consists of light with a wavelength between 100 nm and 400 nm, traditionally divided into 3 subgroups: UV-A (400-315 nm), UV- B (315-280 nm) and UV-C (280-100 nm). Short-wavelength UV-C is the most energetic and harmful UV. They are filtered by the ozone layer of the atmosphere and do not reach the surface of the Earth in considerable quantity. Most skin damage is caused by UV-A and UV-B. UV-B rays induce the production of the skin's natural pigment called “melanin”. This is the origin of the phenomenon commonly called "tanning". UV-B also stimulates cells to produce a thicker epidermis. The reactions described above constitute a defense mechanism of the body against UV radiation. The high UV-B energy generates molecular disorders (DNA alteration and protein damage) which, in the long term, saturate and stop the nuclear DNA repair system. This leads to permanent mutations in the genome of the affected cells, which are at the origin of skin cancers. It is then a direct toxicity of UV-B. As for UV-A, it is known that they penetrate the deep layers of the skin, where they produce deleterious effects, in particular within the connective tissue and on the blood vessels. They are in particular at the origin of the phenomenon called "heliodermia", that is to say the premature actinic aging of the skin. Moreover, although UV-B rays are the main cause of skin cancer, UV-A rays also have an indirect contribution to this type of damage. Indeed, UV-A and UV-B are at the origin of the production of free radicals, in particular ROS (Reactive Oxygen Species or reactive oxygen species (ROS)). These are very unstable molecules with a very short half-life, of the order of a nanosecond to a millisecond. ROS are capable of damaging intracellular structures (DNA, membranes, intracellular proteins, etc.) as well as extracellular structures (components of the extracellular matrix such as collagen fibers, etc.). ROS also exert an indirect harmful action, by causing the oxidation of membrane lipids, which induces the formation of reactive carbonyl species which contribute to amplifying tissue and cellular damage. It is therefore necessary to fight against the harmful effects of UV radiation, in particular UV-A and UV-B, taking into account inter-individual differences such as skin type (phototype) and sun exposure times. For this reason, sunscreen compositions have been developed to ensure photo-protection of areas subject to UV radiation. These compositions are in the form of a lotion, an oil, an emulsion of the oil-in-water or water-in-oil type, a mousse, a gel, a stick or a spray. They contain a cosmetically acceptable carrier and one or more chemical filters or mineral screens at various concentrations. Mineral sunscreens, including zinc oxides and titanium dioxides, provide UV protection by reflecting sunlight. They therefore act as localized mirrors on the surface of the skin. Mineral screens, at least in the micrometer formula, are safe for human use and pose no health risk. However, they have other drawbacks: - mineral screens tend to dry out the skin and spread with difficulty, leaving white streaks on the skin which can be very unsightly; - the galenic assessment of compositions based on mineral screens is often mediocre, in particular in compositions free of silicones. Chemical filters are organic compounds that absorb light by creating a filtering layer on the skin that neutralizes UV rays. Thus, when the solar filter molecule receives UV radiation, it passes into an excited state by absorbing the energy of the radiation and then returns to its stable state. By this mechanism, light radiation is converted into heat and dissipated. Chemical filters therefore act in the same way as melanin, the skin's natural photoprotective pigment. The chemical or organic filters are mostly lipophilic and therefore lend themselves to implementation in highly water-resistant compositions. From a galenic point of view, the compositions based on organic screening agents are, in general, more appreciated than those based on mineral screens, which makes it possible to improve compliance by users. In Europe, all the organic filters or mineral screens, authorized by the regulations, are included in a list (appendix VI of the European Directive on cosmetic products). This is a list currently grouping around thirty compounds according to their INCI designation, from which the cosmetics industry must draw in order to formulate sun protection products. However, this list is not set in stone and is constantly evolving according to the results of scientific research. Indeed, several studies have shown that some of the organic filters on this list could be the source of risk for human health and the environment, in particular because they are suspected of acting as endocrine disruptors. In particular, scientific results cast doubt on the safety of benzophenone-4 or even benzophenone-3 (Kinnberg et al. 2015; Zucchi et al. 2011), octyl methoxycinnamate (Szwarcfarb et al. 2008, Axelstad et al. 2011) 3-methylbenzylidene camphor and 4-methylbenzylidene camphor (Schlumpf et al. 2008; Petersen et al. 2007), octocrylene, isoamyl methoxycinnamate, or octyl dimethyl PABA (Schlumpf et al. 2001; Rehfeld et al. 2016; Ozáez et al. 2016). In parallel with the possible effects in humans, we cannot ignore the effect of these molecules on natural environments; in fact, the filters are continuously dispersed in the bathing water or in the waste water. This water pollution, associated with UV filters, inevitably affects the entire food chain, with unpredictable consequences on the balances of an ecosystem already compromised by human activities; among other examples of ecotoxic effects, sunscreens would have a negative impact on marine reefs and would be responsible in particular for the phenomenon of coral bleaching (Danovaro et al. 2008). The gradual reduction in the number of organic sun filters, considered safe for human use and for the environment, increasingly complicates the formulation of sun cosmetic products, in particular sun products with a high protection factor, i.e. say with an SPF (“Sun protection factor”) greater than 20 or even 30. The formulation of high sun protection products is particularly difficult in the case of products intended for the Canadian and American market, where only a part of the latest generation filters used in Europe for two decades is authorized. To compensate for the reduction in the number of usable sun filters, sun protection agents are often formulated in cosmetic products. These sunscreen agents are sometimes molecules similar to authorized sunscreens, or derivatives of plastics, which can therefore suffer from the same drawbacks as organic sunscreens; in particular, their ecotoxicity could be significant. An interesting family of protective agents is represented by mycosporin analog amino acids (or MAA, for mycosporin-like amino-acids). MAAs are small heterocyclic molecules (<400 Da) comprising cyclohexenone or cyclohexenimine chromophores. MAAs are naturally found as secondary metabolites in marine organisms, such as corals, algae and cyanobacteria, so they are expected to be eco-compatible and respectful of aquatic ecosystems. In particular, document EP2855441 discloses a family of compounds, of MAA type, having the following general formula IE:

This document specifies that these compounds, of the IE molecule family, absorb ultraviolet radiation and can be used as an anti-UV agent. Examples are given of the compounds of formulas IA1 and IE4 having a sun protection factor of 2.4 and 4.5 respectively. Thus, although the MAAs of the IE molecule family absorb UV radiation, the sun protection factor is insufficient for use in sun cosmetic compositions. Although perceived as good candidates for the formulation of eco-compatible sunscreen products, a solution should be found to improve the anti-UV potential of MAAs, in order to be able to use them in sunscreen products. Thus, the aim of the present invention is to overcome the drawbacks of the state of the art, by proposing a composition, in particular ecobiological, comprising MMA and whose SPF is compatible with a topical sunscreen application. Presentation of the invention The Applicant has observed that, quite surprisingly, the fact of combining MMA with at least two organic UVB and/or broad-spectrum filters in the presence of at least one organic UVA filter makes it possible to obtain an SPF of the combination of a value greater than that of the sum of the respective SPFs of the MAAs and the organic filters. This combination therefore lends itself to their use in compositions with high sun protection at relatively low levels of organic screening agents. Thus, according to a first aspect, the invention relates to a composition, in particular a cosmetic or dermatological composition, comprising: at least one amino acid analogue of mycosporin called “MAA”; -at least two UVB organic filters and/or at least two broad-spectrum organic filters; -at least one organic UVA filter. According to another aspect, the invention relates to a composition, in particular a cosmetic or dermatological composition, comprising: - at least one amino acid analog of mycosporin called "MAA" chosen from the group consisting of molecules A of formula IA or a of its acceptable salts, and/or the group consisting of molecules B of formula IB or one of its acceptable salts, said formula IA being: Wherein: R1 is hydrogen; alkyl; alkenyl; alkynyl; aryl; heterocycle; cycloalkyl; alkoxy; alkanoyl; hydroxyl; a sulfo group; a halogen group; a phosphono group; an ester group; a carboxylic acid group; a phenyl group; an amino group; an alkylated fatty acid chain or a polyether; R2 is alkyl; alkenyl; alkynyl; aryl; heterocycle; cycloalkyl; alkoxy; alkanoyl; a sulfo group; a phosphono group; an ester group; a carboxylic acid group; hydroxyl; or a phenyl group; said composition further comprises: - at least two organic screening agents chosen from UVB organic screening agents and/or broad-spectrum organic screening agents absorbing in both UVB and UVA rays; -at least one organic UVA filter. According to a particular embodiment, the composition according to the invention is ecobiological. By “ecobiological composition”, we mean respectful of people, their interactions with the world, and the planet. The MAAs according to the invention are known to those skilled in the art and described for example in patent application WO2013/181741 which details their process for obtaining and purifying them. According to a particular embodiment, R1 is an alkoxy group of the [CH3]-[CH2]nO- type, where “n” is between 0 and 10. According to a preferred embodiment, “n”=0 or “n »=8. According to a particular embodiment of the invention, R2 is a carboxylic acid group of the [COOH]-[CH2]n- type, where “n” is between 0 and 5, where preferably “n”=1 or “ n”=0. According to an alternative embodiment of the invention, R2 is an ester group of the type [CH ₃ ]-[CH2]n-[COOH]-, where "n" is between 0 and 5, where preferably "n" =1 or “n”=2. According to another particular embodiment, R1 is an alkoxy group of the [CH3]-[CH2]nO- type, where “n”=0; and ; R2 is an ester group of the type [CH3]-[CH2]n-[COOH] -, where "n"=1 or "n"=2 or R2 is a carboxylic acid group of the type [COOH]-[CH2]n -, where “n” is between 0 and 5, where preferably “n”=1 or “n”=0. Thus, and according to a particular embodiment, the MAA according to formula IA corresponds to the molecule of formula IIA1 below: Formula IIA1: This molecule of formula IIA1: [N-[(3E)-3-[(4-methoxyphenyl)imino]-5,5-dimethyl-1-cyclohexen-1-yl]-Glycine, corresponding to CAS number 1509902-01- 5] is marketed by ELKIMIA Inc. under the INCI designation methoxyphenylimino dimethylcyclohexene glycine. In another embodiment, the MAA according to formula IA corresponds to the molecule of formula IIA2 below: Formula IIA2: This molecule of formula IIA2: [N-[3-[(4-methoxyphenyl)amino]-5,5-dimethyl-2-cyclohexen-1-ylidene]-, ethyl ester, [N(E)]-Glycine, corresponding with CAS number 2640340-86-7] is available from the company SENSIENT Inc. under the trade name SENSISORB™ BIOMIM (INCI: methoxyphenylimino dimethylcyclohexenyl ethyl glycinate). According to a preferred embodiment, the MAA according to formula IB corresponds to the molecule of formula IIB1 below: Formula IIB1 This molecule of formula IIB1 [3,5,6,7-tetrahydro-6,6-dimethyl-8-[[4-(octyloxy)phenyl]amino]-2H-1,4-Benzothiazine-3-carboxylic acid, corresponding with CAS number 1629023-01-3] is marketed by the company ELKIMIA Inc. under the INCI designation caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid. According to an alternative embodiment, the MAA according to formula IB corresponds to the molecule of formula IIB2 below: Formula IIB2 This molecule of formula IIB2 [3,5,6,7-tetrahydro-8-[(4-methoxyphenyl)amino]-6,6-dimethyl-2H-1,4-Benzothiazine-3-carboxylic acid corresponding to CAS number 1629023 -04-6] is marketed by the company ELKIMIA Inc. under the INCI designation methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid. According to an alternative embodiment, the MAA according to formula IB corresponds to the molecule of formula IIB3 below. Formula IIB3 This molecule of formula Ethylester- (3R)- 2H-1,4-Benzothiazine-3-carboxylic acid, 3,4,5,6,7,8- hexahydro-8-[(4-methoxyphenyl)imino]-6, 6-dimethyl corresponds to CAS number 2699128-33-9. In a particular embodiment of the invention, the compositions according to the invention contain at least two MAAs as defined previously, in particular chosen from molecules corresponding to the INCI designations methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid and methoxyphenylimino dimethylcyclohexenyl ethyl glycinate as well as possibly the compound corresponding to CAS number 2699128-33-9. According to one particular embodiment, the compositions according to the invention contain at least three MAAs. By “acceptable salts”, within the meaning of the invention, is meant any pharmacologically or cosmetically acceptable salt of MAA, such as, for example, salts of the sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, isonicotinate, lactate, salicylate, citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p- toluenesulfonate, pamoate and hydroxy-3-naphthoate. According to a particular embodiment, the MAA(s) represent(s) between 0.1% and 20% by mass relative to the total mass of the composition, preferably between 0.5% and 10%, even more advantageously between 1 and 2%. The term "organic sunscreen" denotes organic UVB filters, organic UVA filters and broad-spectrum organic filters. By “organic UVB filter”, within the meaning of the invention, is meant any organic sunscreen, whether hydrophilic or lipophilic, which absorbs mainly or exclusively in UVB. According to a particular embodiment, the organic UVB filter is chosen from salicylates. More particularly, the organic UVB filter is chosen from the compounds corresponding to the following INCI designations: ethylhexyl salicylate and homosalate or else phenylbenzimidazole sulphonic acid or ethylhexyl triazone. A source of the latter is the raw material UVINUL™ T150 marketed by the company BASF. The organic UVB filter corresponding to the INCI designation phenylbenzimidazole sulfonic acid, for its part, is available from the company AAKO BV under the name AakoSun PBSA. The salicylates corresponding to the INCI designations octyl salicylate and homosalate are available from the company SYMRISE under the names, respectively, of Neo Heliopan™ OS and Neo Heliopan™ HMS. According to a particular embodiment of the invention, said at least one organic UVB filter represents between 1% and 20% by mass relative to the total mass of the composition, preferably between 2% and 15%. By “organic UVA filter”, within the meaning of the invention, is meant any organic sunscreen, whether hydrophilic or lipophilic, which absorbs mainly or exclusively in UVA. According to a preferred embodiment, the composition according to the invention comprises at least one UVA sunscreen chosen from the group comprising the compounds corresponding to the following INCI designations: butyl methoxydibenzoylmethane, diethylamino hydroxybenzoyl hexyl benzoate, bis-(diethylaminohydroxybenzoyl benzoyl) piperazine, disodium phenyl dibenzimidazole tetrasulfonate, especially butyl methoxydibenzoylmethane and diethylamino hydroxybenzoyl hexyl benzoate. By way of example, the UVA filters according to the invention correspond to the raw material Parsol 1789® (INCI: butyl methoxydibenzoylmethane) marketed by the company DSM; the raw material UVINUL™ A+ (INCI: diethylamino hydroxybenzoyl hexyl benzoate) marketed by the company BASF; the raw material C1332™ [INCI: bis-(diethylaminohydroxybenzoyl benzoyl) piperazine; CAS number 919803-06-8] marketed by the company BASF; or else the material Neo Heliopan™ AP corresponding to the INCI designation disodium phenyl dibenzimidazole tetrasulfonate, and marketed by the company SYMRISE. According to a particular embodiment, said at least one organic UVA screening agent represents between 1% and 10% by weight relative to the total weight of the composition, preferably between 2% and 7%. By “broad-spectrum organic filter”, within the meaning of the invention, is meant any organic sunscreen, whether hydrophilic or lipophilic, which absorbs both UVB and UVA rays. According to a preferred embodiment, the composition according to the invention comprises at least one broad-spectrum sunscreen chosen from the group comprising the compounds corresponding to the following INCI designations: bis ethylhexyloxyphenol methoxyphenyl triazine, diethylhexyl butamido triazone, tris-biphenyl triazine, phenylene bis-diphenyltriazine, methylene bis-benzotriazolyl tetramethylbutylphenol and drometrizole trisiloxane, in particular bis-ethylhexyloxyphenol methoxyphenyl triazine, diethylhexyl butamido triazone, tris-biphenyl triazine, methylene bis-benzotriazolyl tetramethylbutylphenol. These sunscreens are available from the following suppliers: - PARSOL™ Shield marketed by the company SYMRISE and corresponding to the INCI designation: bis ethylhexyloxyphenol methoxyphenyl triazine; - UVASORB™ HEB marketed by the company SIGMA 3V and corresponding to the INCI designation: diethylhexyl butamido triazone; - TINOSORB™ A2B marketed by BASF and corresponding to the INCI designation tris-biphenyl triazine; - the TRIASORB™ marketed by the company PLANTES & INDUSTRIE and corresponding to the INCI designation: phenylene bis-diphenyltriazine (CAS number 55514-22-2); - MEXORYL™ XL, corresponding to the INCI designation: drometrizole trisiloxane; - TINOSORB™M marketed by BASF and corresponding to the INCI designation: methylene bis-benzotriazolyl tetramethylbutylphenol. According to a particular embodiment, said at least one broad-spectrum organic screening agent represents between 1% and 15% by mass relative to the total mass of the composition, preferably between 2% and 10%. According to a particular embodiment, the composition according to the invention comprises: at least one MAA as defined above, in particular chosen from the group consisting of the molecules corresponding to the INCI designations methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as possibly the compound corresponding to CAS number 2699128-33-9, -at least two organic UVB filters; -at least one organic UVA filter. According to an alternative embodiment, the composition according to the invention comprises: at least one MAA as defined above, in particular chosen from the group consisting of the molecules corresponding to the INCI designations methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as possibly the compound corresponding to CAS number 2699128-33-9; -at least two broad-spectrum organic filters; -at least one organic UVA filter. According to yet another embodiment, the composition according to the invention comprises: - at least one MAA as defined above, in particular chosen from the group consisting of the molecules corresponding to the INCI designations methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as possibly the compound corresponding to CAS number 2699128-33-9; -at least one organic UVB filter; at least one broad-spectrum organic filter; -at least one organic UVA filter. According to yet another embodiment, the composition according to the invention comprises: - at least one MAA as defined above, in particular chosen from the group consisting of the molecules corresponding to the INCI designations methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as possibly the compound corresponding to CAS number 2699128-33-9; -at least one organic UVB filter; -at least two broad-spectrum organic filters; -at least one organic UVA filter. According to yet another embodiment, the composition according to the invention comprises: at least one MAA as defined above, in particular chosen from the group consisting of the molecules corresponding to the INCI designations methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as possibly the compound corresponding to CAS number 2699128-33-9; -at least two organic UVB filters; at least one broad-spectrum organic filter; -at least one organic UVA filter. According to another aspect, the composition according to the invention comprises: at least one MAA as defined above, in particular chosen from the group consisting of the molecules corresponding to the INCI designations methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as possibly the compound corresponding to CAS number 2699128-33-9; -at least 2 UVB filters corresponding to the following INCI designations: octyl salicylate and homosalate; - at least the UVA organic filter corresponding to the following INCI designation: butyl methoxydibenzoylmethane. According to another embodiment, the composition according to the invention comprises as MAAs and organic sunscreens: - an MAA chosen from the group consisting of the molecules corresponding to the INCI designations methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as optionally the compound corresponding to CAS number 2699128-33-9, advantageously methoxyphenylimino dimethylcyclohexene glycine; - 2 UVB filters corresponding to the following INCI designations: octyl salicylate and homosalate; - an organic UVA filter corresponding to the following INCI designation: butyl methoxydibenzoylmethane. According to another embodiment, the composition according to the invention comprises as MAAs and organic sunscreens: - two MAAs chosen from the group consisting of the molecules corresponding to the INCI designations methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as possibly the compound corresponding to CAS number 2699128-33-9, advantageously methoxyphenylimino dimethylcyclohexene glycine and methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid and methoxyphenylimino dimethylcyclohexenyl ethyl glycinate; - 2 UVB filters corresponding to the following INCI designations: octyl salicylate and homosalate; - an organic UVA filter corresponding to the following INCI designation: butyl methoxydibenzoylmethane. According to a particular embodiment, the composition according to the invention comprises: at least one MAA as defined above, in particular chosen from the group consisting of the molecules corresponding to the INCI designations methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as possibly the compound corresponding to CAS number 2699128-33-9; -at least 2 UVB filters, corresponding to the following INCI designations: octyl salicylate and homosalate; - at least the UVA organic filter corresponding to the following INCI designation: diethylamino hydroxybenzoyl hexyl benzoate. According to a different embodiment, the composition according to the invention comprises: at least one MAA as defined above, in particular chosen from the group consisting of the molecules corresponding to the INCI designations methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as possibly the compound corresponding to CAS number 2699128-33-9; -at least two broad-spectrum filters corresponding to the following INCI designations: diethylhexyl butamido triazone and bis-ethylhexyloxyphenol methoxyphenyl triazine; -at least one UVA sunscreen chosen from the group comprising the compounds corresponding to the following INCI designations: butyl methoxydibenzoylmethane, diethylamino hydroxybenzoyl hexyl benzoate, bis-(diethylaminohydroxybenzoyl benzoyl) piperazine, disodium phenyl dibenzimidazole tetrasulfonate, in particular butyl methoxydibenzoylmethane and diethylamino hydroxybenzoyl hexyl benzoate, advantageously butyl methoxydibenzoylmethane and diethylamino hydroxybenzoyl hexyl benzoate. According to a different embodiment, the composition according to the invention comprises: at least one MAA as defined above, in particular chosen from the group consisting of the molecules corresponding to the INCI designations methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as possibly the compound corresponding to CAS number 2699128-33-9; -at least two broad-spectrum filters corresponding to the following INCI designations: diethylhexyl butamido triazone and bis-ethylhexyloxyphenol methoxyphenyl triazine; -at least one UVA sunscreen corresponding to the following INCI designation: diethylamino hydroxybenzoyl hexyl benzoate. According to another embodiment, the composition according to the invention comprises as MAAs and organic sunscreens: - an MAA as defined above, in particular chosen from the group consisting of the molecules corresponding to the INCI designations methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as optionally the compound corresponding to CAS number 2699128-33-9, advantageously methoxyphenylimino dimethylcyclohexene glycine; - two broad-spectrum filters corresponding to the following INCI designations: diethylhexyl butamido triazone and bis-ethylhexyloxyphenol methoxyphenyl triazine; - a UVA sunscreen corresponding to the following INCI designation: diethylamino hydroxybenzoyl hexyl benzoate. According to an alternative embodiment, the composition according to the invention comprises: --at least one MAA as defined above, in particular chosen from the group consisting of the corresponding molecules corresponding to the INCI designations methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid , methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as possibly the compound corresponding to CAS number 2699128-33-9; at least broad-spectrum filters corresponding to the following INCI designations: diethylhexyl butamido triazone and bis-ethylhexyloxyphenol methoxyphenyl triazine; at least the organic UVB filter corresponding to the following INCI designation: ethylhexyl triazone; -at least the UVA organic filter corresponding to the following INCI designation: butyl methoxydibenzoylmethane. According to a particular embodiment, the composition according to the invention comprises: at least one MAA as defined above, in particular chosen from the group consisting of the corresponding molecules corresponding to the INCI designations methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate and possibly the compound corresponding to CAS number 2699128-33-9; at least the broad-spectrum organic screening agents corresponding to the following INCI designations: diethylhexyl butamido triazone and bis-ethylhexyloxyphenol methoxyphenyl triazine; at least the organic UVB filter corresponding to the following INCI designation: ethylhexyl triazone; -at least the UVA organic filter corresponding to the following INCI designations: diethylamino hydroxybenzoyl hexyl benzoate. According to a particular embodiment, the composition according to the invention is free of at least one, alternatively sunscreens corresponding to the following INCI designations: 4-methylbenzylidene camphor, 3-methylbenzylidene camphor, benzophenone-2, benzophenone-3, benzophenone-4, ethylhexyl methoxycinnamate, isoamyl methoxycinnamate, octocrylene, octyl dimethyl PABA. Preferably, the composition additionally includes at least one sunscreen solubilizer. Within the meaning of the invention, the term "solubilizer" denotes a compound which makes it possible to solubilize, disperse and/or dissolve at least one triazine-derived sunscreen in an effective and lasting manner, that is to say by stabilizing it in its solubilized form and by preventing or reducing its recrystallization or precipitation in formulation throughout the period of use of the product. Thus, the compositions according to the invention additionally comprise at least one solubilizer chosen from the group comprising the compounds corresponding to the following INCI designations: caprylyl caprylate/caprate, dibutyl adipate, dicaprylyl carbonate, diisopropyl sebacate, dicaprylyl ether, coco-caprylate , C12-15 alkyl benzoate, propylheptyl caprylate, butylene glycol dicaprylate/dicaprate, dipropylene glycol dibenzoate, neopentyl glycol diheptanoate, triheptanoin, C12-13 alkyl lactate, ethylhexyl benzoate, C12-C15 alkyl lactate, C12-13 alkyl tartrate , tridecyl salicylate , lauryl lactate, diethyl adipate, diisobutyl adipate, diisopropyl adipate, diethylhexyl adipate, diethylhexyl succinate, propanediol dicaprylate, propylene glycol dicaprylate/dicaprate, isopropyl lauroyl sarcosinate, propylene glycol dibenzoate, hydroxyl dimethoxybenzyl malonate, phenoxyethyl caprylate, isodecyl salicylate, dimethyl capramide and phenethyl benzoate , in particular at least two solubilizers chosen from ns the following group: caprylyl caprylate/caprate, dibutyl adipate, dicaprylyl carbonate, diisopropyl sebacate, dicaprylyl ether, coco-caprylate, C12-15 alkyl benzoate, propylheptyl caprylate, butylene glycol dicaprylate/dicaprate. Solubilizers capable of being implemented in a composition according to the invention are available on the market from several suppliers. By way of example, the following raw materials can be used in the composition according to the invention: - Several raw materials from the CETIOL™ range marketed by the company BASF, in particular CETIOL™ RLF, CETIOL™ B, CETIOL™ CC, CETIOL™ O, CETIOL™ C5, CETIOL™ AB, CETIOL™ SENSOFT corresponding respectively to the following INCI designations: caprylyl caprylate/caprate, dibutyl adipate, dicaprylyl carbonate, dicaprylyl ether, coco-caprylate, C12-15 alkyl benzoate, propylheptyl caprylate; - DUB™ DIS, DEA, DIBA, ZENOAT marketed by the company STEARINE DUBOIS corresponding respectively to the following INCI designations: diisopropyl sebacate, diethyl adipate, diisobutyl adipate and propanediol dicaprylate; - MIGLYOL™ 8810 and MIGLYOL™ T-C7 marketed by the company IOI Oleo GmbH corresponding respectively to the following INCI designations butylene glycol dicaprylate/dicaprate and triheptanoin; - Lexsolv™ A marketed by the company INOLEX corresponding to the following INCI designations: dipropylene glycol dibenzoate and neopentyl glycol diheptanoate; - The COSMACOL™ ELI, ETI, ESI and LL marketed by SASOL and corresponding respectively to the following INCI designations: C12-13 alkyl lactate, C12-13 alkyl tartrate, tridecyl salicylate and lauryl lactate; - The Ceraphyl™ 41 ester marketed by the company ASHLAND and corresponding to the following INCI designation C12-C15 alkyl lactate; - Finsolv™ EB and PG 22 marketed by INNOSPEC and corresponding respectively to the following INCI designations: ethylhexyl benzoate and dipropylene glycol dibenzoate; - The CRODAMOL™ DA, DOA, OSU and PC marketed by the company CRODA and corresponding respectively to the following INCI designations: diisopropyl adipate, diethylhexyl adipate, diethylhexyl succinate and propylene glycol dicaprylate/dicaprate; - ELDEW™ SL-205 marketed by the company AJINOMOTO and corresponding to the following INCI designation: isopropyl lauroyl sarcosinate; - Lexfeel™ Shine marketed by the company INOLEX and corresponding to the INCI designation propylene glycol dibenzoate; - TEGOSOFT™ XC marketed by the company EVONIK and corresponding to the following INCI designation: phenoxyethyl caprylate; - RONACARE™ AP marketed by MERCK KGaA and corresponding to the following INCI designation: hydroxyl dimethoxybenzyl malonate; - DERMOL™ IDSA marketed by the company Alzo INTL and corresponding to the following INCI designation: isodecyl salicylate; - Spectrasolv™ DMDA marketed by Hallstar and corresponding to the following INCI designation: dimethyl capramide; - X-TEND™ 226 marketed by the company Ashland and corresponding to the following INCI designation: phenethyl benzoate. According to a particular embodiment, the composition according to the invention comprises at least three solubilizers chosen from the group comprising the compounds corresponding to the following INCI designations: caprylyl caprylate/caprate, dibutyl adipate, dicaprylyl carbonate, diisopropyl sebacate, dicaprylyl ether, coco- caprylate, C12-15 alkyl benzoate, propylheptyl caprylate, butylene glycol dicaprylate/dicaprate. According to one particular embodiment, the composition according to the invention comprises at least the solubilizers corresponding to the following INCI designations: dibutyl adipate, dicaprylyl carbonate and diisopropyl sebacate. According to another embodiment, the composition according to the invention comprises at least the solubilizers corresponding to the following INCI designations: dibutyl adipate, dicaprylyl carbonate, diisopropyl sebacate and propylheptyl caprylate. According to a particular embodiment, the solubilizers represent between 5% and 80% by mass relative to the total mass of the composition, advantageously between 10% and 70%, preferably between 15% and 60%. According to a particular embodiment, the composition according to the invention comprises mineral screens (or inorganic mineral filters), which correspond to metal oxides and/or other compounds that are not easily soluble or insoluble in water, in particular oxides titanium (TiO ₂ ), zinc (ZnO), iron (Fe ₂ O ₃ ), zirconium (ZrO ₂ ), silicon (SiO ₂ ), manganese (for example MnO), aluminum (Al ₂ O ₃ ), or cerium (Ce ₂ O ₃ ), or even bismuth trioxide (Bi2O3). Inorganic mineral filters can also be surface-treated or encapsulated, in order to give them a hydrophilic, amphiphilic or hydrophobic character. This surface treatment may consist in the mineral filters being provided with a thin hydrophilic and/or hydrophobic inorganic and/or organic film. According to a particular embodiment, the composition according to the invention comprises at least one mineral screen chosen from the group comprising the compounds corresponding to the following INCI designations: zinc oxide, titanium dioxide and mixtures thereof. By way of example, zinc oxide corresponds to the raw material Z-COTE ^® LSA and titanium dioxide to the raw material T-Lite ^® , marketed by the company BASF. The lists of UV filters mentioned that can be implemented within the meaning of the present invention are of course given as an indication and not limiting. According to a particular embodiment, the composition according to the invention has a so-called “SPF” sun protection factor equal to or greater than 20, advantageously equal to or greater than 30, preferably equal to or greater than 40, or even equal to or greater than 50. According to a preferred embodiment, the composition according to the invention comprises a UV-A/UV-B protection ratio equal to or greater than 1/3. In particular, the composition according to the invention has a critical wavelength (λc) greater than 370 nm. This value, which is determined by in vitro methods known to those skilled in the art, corresponds to the wavelength for which the integral of the curve of the absorption spectrum starting at 290 nm reaches 90% of the integral between 290 and 400 nm. The composition according to the invention may also comprise an SPF "booster", that is to say an agent for enhancing the sun protection factor, and/or a photo-stabilizer, that is to say an ingredient which makes it possible to increase the SPF or to photo-stabilize the filters, such an ingredient not being considered itself as a sunscreen. For example, we can cite: - butyloctyl salicylate (INCI), photostabilizer advantageously representing between 0.01% and 10% by weight relative to the total weight of the composition, even more advantageously between 0.1% and 2%. This raw material is, for example, marketed by the company HALLSTAR under the name Hallbrite™ BHB; - benzotriazolyl dodecyl p-cresol (INCI), light stabilizer advantageously representing between 0.01% and 10% by weight relative to the total weight of the composition, even more advantageously between 0.1% and 2%. This raw material is, for example, marketed by the company BASF under the name of TINOGARD™ TL; - pongamol (INCI), plant molecule absorbing in UV-A, advantageously representing between 0.5 and 2% by weight relative to the total weight of the composition, even more advantageously of the order of 1%. By way of example, the raw material Pongamia Extract marketed by the company GIVAUDAN can be used in the context of the present invention; - ethylhexyl methoxycrylene (INCI), light stabilizer, solubilizer and SPF “booster”, advantageously representing between 1% and 5% by weight relative to the total weight of the composition. The SolaStay™ S1 raw material marketed by the company HALLSTAR can be used in the context of the present invention; - a styrene acrylate copolymer (INCI: styrene/acrylate copolymer), preferably representing between 1% and 10% by weight relative to the total weight of the composition according to the invention. The raw materials SunSpheres™ H53 and SunSpheres™ PGL Polymer, marketed by the company DOW CHEMICALS, can be used in the context of the present invention; - diethylhexyl syringylidene malonate (INCI), advantageously representing between 1% and 10% by weight relative to the total weight of the composition. The OXYNET™ ST raw material, marketed by the company MERCK, can be used in the context of the present invention; - a water-dispersible polyester, corresponding to the INCI designations polyester-5 (and) Sodium silicoaluminate, advantageously representing between 1% and 10% by weight relative to the total weight of the composition, in particular EASTMANN AQTM38S Polymer marketed by the company SAFIC-ALCAN ; - an acrylate copolymer having a glass transition temperature of -5°C to -15°C as measured by differential scanning calorimetry, said copolymer advantageously representing between 1% and 10% by weight relative to the total weight of the composition. Through For example, a polymer corresponding to the INCI designation Acrylate copolymer, such as the raw material EPITEX 66, marketed by the company DOW CHEMICALS, can be used in the context of the present invention. In a preferred embodiment, the composition according to the invention further comprises other components which may contribute to internal protection by an action which may consist of DNA protection, a reduction in the immunosuppression induced by UV radiation, an anti-radical action or a combined effect of these actions. The protective action of a composition according to the invention against oxidative stress or against the effect of free radicals can be further improved if it additionally comprises one or more antioxidants, easily selected by the skilled in the art, for example from the following list: totarol, magnolol, honokiol, amino acids and their derivatives, peptides (D and/or L-carnosine) and their derivatives (for example anserine, l hypotaurine, taurine), carotenoids, carotenes (α-carotene, β-carotene, lycopene) and their derivatives, chlorogenic acid and its derivatives, lipoic acid and its derivatives (dihydrolipoic acid), aurothioglucose , propylthiouracil and other thiols (thioredoxin, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, γ-linoleic, cholesterol and glyceryl esters) as well as as salts thereof, dilauryl thiodipropionate, thiodiprop distearyl ionate, thiodipropionic acid and its derivatives, sulfoximine compounds (buthionine sulfoximine, homocysteine sulfoximine, buthionine sulfones, penta-, hexa-, and heptathionine sulfoximine), chelating agents (such as α-hydroxy fatty acids , palmitic acid, phytic acid, lactoferrin), α-hydroxy acids (such as citric, lactic, or malic acid), humic acid, bile acid, bile extracts, bilirubin , biliverdin, ethylenediamine pentasodium tetramethylene phosphonate and its derivatives, unsaturated fatty acids and their derivatives, vitamin A and its derivatives (vitamin A palmitate), coniferyl benzoate of benzoin resin, rutinic acid and its derivatives, α-glycosyl rutin, ferulic acid and its derivatives, furfurylideneglucitol, carnosine, butylhydroxytoluene, butylhydroxyanisole, nordihydroguaiaretic acid, trihydroxybutyrophenone, quercetin, uric acid and its derivatives, mannose and derivatives thereof, zinc and its derivatives (ZnO, ZnSO4), selenium and its derivatives (selenomethionine), stilbenes and their derivatives (stilbene oxide, trans-stilbene oxide). In a particular embodiment, the composition according to the invention also comprises glycyrrhetinic acid, a derivative or a salt of this acid, used as a soothing agent (anti-inflammatory agent) and representing between 0.01% and 2% by weight relative to the total weight of the composition, preferably between 0.1% and 1%. According to another preferred characteristic of the invention, the cosmetic and/or dermatological composition comprises at least one, or even all of the following constituents exerting a biological activity in vivo on the cells of the skin, lips, hair and/or mucous membranes subjected to UV-A and/or UV-B radiation, respectively: - an anti-radical agent preserving cellular structures, such as for example vitamin E and/or its fat-soluble or water-soluble derivatives, in particular tocotrienol and/or tocopherol, advantageously representing between 0.001 and 10% by weight relative to the total weight of the composition, even more advantageously between 0.02 and 2%, preferably of the order of 0.04%; - an agent limiting immunosuppression, such as for example vitamin PP, advantageously representing between 0.001 and 1% by weight relative to the total weight of the composition, even more advantageously from 0.01% to 0.3%; - a protective agent for the p53 protein, such as for example epigallocatechin gallate (EGCG), advantageously representing between 0.001 and 0.1% by weight relative to the total weight of the composition, even more advantageously from 0.005% to 0, 05%. The composition according to the invention may also comprise, in addition, peptide extracts of soybeans and/or wheat, such as those described in document EP 2059230. In practice, the peptide extracts, which come from soybeans and wheat , are derived from an enzymatic hydrolysis of said seeds via peptidases which make it possible to recover peptides with an average size of 700 Daltons. Preferably, the soy peptide extract is the extract identified under CAS number 68607-88-5, as well as the extract wheat peptide is the extract identified under CAS number 70084-87-6. Wheat and soy extracts may respectively correspond to the following INCI designations: Hydrolyzed wheat protein and Hydrolyzed soy protein. In a particular embodiment, the peptide extracts of soybean and/or wheat are used together, for example in a weight ratio respectively comprised between 80/20 and 20/80, advantageously comprised between 70/30 and 30/70, of preference equal to 60/40. In a particular embodiment, the soybean and/or wheat peptide extracts are free of synthetic GHK tripeptides (glycyl-histidyl-lysine; INCI: Tripeptide-1). In practice, the peptide extracts of soya and/or wheat representing from 0.01 to 20% by weight relative to the total weight of the composition, advantageously from 0.1% to 10%, even more advantageously from 0.2% to 0.7%. In an alternative embodiment, the composition according to the invention comprises, in accordance with the teachings of document FR 2865398, the combination of at least one amino acid chosen from the group consisting of ectoine, creatine, ergothioneine and / or carnosine, or their physiologically acceptable salts, and mannitol or a mannitol derivative. Preferably, the composition according to the invention comprises, in a physiologically acceptable medium, the amino acid or one of its salts, alone or as a mixture in proportions of between 0.001% and 10% by weight relative to the total weight of the composition, and preferably between 0.01% and 5%. The composition according to the present invention preferably comprises, in a physiologically acceptable medium, mannitol or one of its derivatives, in proportions of between 0.01% and 30% by weight relative to the total weight of the composition, advantageously between 0.1% and 10%. In a preferred embodiment, the composition according to the invention comprises ectoin and mannitol. According to a particular embodiment, the composition according to the invention comprises one or more other tanning or self-tanning agents. It can be a self-tanner which reacts with the amino acids of the skin according to a Maillard reaction or via a Michael addition, or else a promoter of melanogenesis or a propigmenting compound which promotes tanning natural to the skin. Such a tanning or self-tanning agent is preferably present in the composition in an amount ranging from 0.01% to 20% by weight relative to the total weight of the composition, advantageously from 0.5% to 15%, even more advantageously from 1 % at 8%. Self-tanning substances can be 1,3-dihydroxyacetone (DHA), glycerolaldehyde, hydroxymethylglyoxal, γ-dialdehyde, erythrulose, 6-aldo-D-fructose, ninhydrin, 5-hydroxy-1 ,4-naphthoquinone (juglone), 2-hydroxy-1,4-naphthoquinone (lawsone), or their combination. Propigmenting substances can be melanocyte-stimulating hormone (α-MSH), α-MSH peptide analogues, endothelin-1 receptor agonists, opioid µ receptor agonists, cAMP, tyrosinase stimulating agents. In a particular embodiment, the composition according to the invention further comprises, as a self-tanner, a combination of dihydroxy methylchromonyl palmitate and/or dimethylmethoxy chromanol, as well as a lipophilic form of tyrosine. This combination of active ingredients effectively stimulates tanning. Dihydroxy methylchromonyl palmitate (CAS number: 1387636-35-2) corresponds, for example, to the cosmetic ingredient marketed by the company MERCK under the name RonaCare™ Bronzyl. Dimethylmethoxy chromanol (CAS number: 83923-51-7) corresponds, for example, to the cosmetic ingredient marketed by the company LIPOTEC SA under the name lipochromone-6. According to a particular embodiment, dihydroxy methylchromonyl palmitate or dimethylmethoxy chromanol is included in the composition according to the invention in the amount of 0.01% to 10% by weight relative to the total weight of the composition, advantageously from 0.05 % to 10%, even more advantageously from 0.1% to 5%, more particularly from 0.1% to 0.5%. The lipophilic form of tyrosine, within the meaning of the invention, is a tyrosine-based ingredient and has a more pronounced lipophilic nature than tyrosine. The lipophilic form of tyrosine may in particular correspond to oleoyl tyrosine (CAS number: 147732-57-8), which is found, for example, in the liquid cosmetic ingredient TYR-OL, marketed by the company SEDERMA, and which comprises approximately 50% by weight of oleoyl tyrosine in butylene glycol (approximately 30%+approximately 20% oleic acid), or else in the liquid cosmetic ingredient TYR-EXCEL, marketed by the company SEDERMA, which comprises approximately 50 % by weight of oleoyl tyrosine, approximately 20% by weight of oleic acid (CAS No: 112-80-1) and approximately 30% by weight of Luffa cylindrica oil (sponge gourd seed oil; CAS: 1242417-48-6). According to another embodiment, the lipophilic form of tyrosine corresponds to a vegetable oil in which the tyrosine has been formulated. According to a particular embodiment, the vegetable oil is oleic sunflower oil, in particular deodorized. Thus, the raw material OLEOACTIVE TYROSINE BASE HELIANTHUS ANNUS marketed by the company OLEOS, and corresponding to the INCI designations Helianthus annuus seed oil (and) tyrosine (and) glyceryl stearate, can be used in the context of the present invention. In practice, the lipophilic form of tyrosine, such as in cosmetic ingredients based on oleoyl-tyrosine (advantageously at 50% by weight) or tyrosine formulated in vegetable oil, represents between 0.1% and 10% by weight relative to the total weight of the composition, advantageously between 1 and 3%, even more advantageously between 1% and 1.5%. The composition according to the invention may also comprise active agents having depigmenting properties, such as for example: - lysine azeilate, or other derivatives or salts of azelaic acid; - andrographolide, in particular the extract of Andrographis paniculata corresponding to the INCI designation Andrographis paniculata leaf extract; - native ascorbic acid (vitamin C) or its derivatives, in particular the derivatives corresponding to the INCI Ascorbyl Glucoside, Ethyl ascorbic acid, Ascorbyl methylsilanol pectinate, Sodium ascorbyl phosphate and Ascorbyl tetraisopalmitate, advantageously ascorbyl glucoside; - arbutin or a plant extract containing it, in particular bearberry extract corresponding to the INCI designation Arctostaphylos uva-ursi leaf extract; - glabridin or a plant extract containing it, in particular liquorice extracts corresponding to the INCI designation Glycyrrhiza glabra root extract, Glycyrrhiza inflata root extract, Glycyrrhiza uralensis root extract; - biomimetic peptides corresponding to the INCI designations hexapeptide 2 and/or nonapeptide-1; - an aqueous extract of an alga called Palmaria palmata, in particular the extract corresponding to the INCI designation Palmaria palmata extract; - 4-n-butylresorcinol; - vitamin PP, also called niacinamide or nicotinamide, and its derivatives; - or mixtures thereof. The composition according to the invention may also comprise active agents having healing properties such as, for example, an antimicrobial agent chosen from the active agents corresponding to the following INCI designations: copper sulphate, zinc sulphate, sodium hyaluronate, Vitis vinifera (grape) vine extract and mixtures thereof. . The composition according to the invention may also comprise active agents having sebocorrective, keratolytic, sebum-regulating properties and/or an anti-acne activity, in order to allow the formulation of sun products treating acne. For example, the composition according to the invention may comprise an antimicrobial agent chosen from the active agents corresponding to the following INCI designations: propyl gallate, dodecyl gallate, Ginkgo biloba leaf extract, bakuchiol, dihydromyricetin, zinc gluconate, salicylic acid and mixtures thereof. The composition according to the invention may therefore also comprise at least one ingredient chosen from the following list: - an agent capable of filtering visible light, in particular blue light; - an extract of Laminaria ochroleuca, Blidingia minima or Laminaria saccharina seaweed; - an extract of the Zanthoxylum alatum plant; - panthenol; - an extract of cade wood; - a Boldo extract; - an extract of Meadowsweet; - an extract of karanja oil from Pongamia glabra; - linear paraffins; - ATP (adenosine-5 tri-phosphate), Gp4G (diguanosine tetraphosphate) or Ap4A (diadenosine tetraphosphate), - an amino acid chosen from the group consisting of decarboxycarnosine, glutamine and their salts. The composition according to the invention may also comprise adjuvants such as those usually used in the field of cosmetics, such as preservatives, antioxidants, complexing agents, solvents, perfumes, fillers, bactericides, electrolytes, odor absorbers, dyestuffs or even lipid vesicles. The choice of these adjuvants, as well as their concentrations, must be determined so that they do not modify the properties and the advantages sought for the composition of the present invention. The composition of the invention is for topical application and more particularly for application to the skin, lips, hair and/or mucous membranes. Thus and in the context of the invention, such a composition is in particular intended for the protection of the skin and/or appendages, in particular the mucous membranes, the lips and the hair, against UV radiation. The composition of the invention can be in all the dosage forms normally used in the cosmetic and dermatological fields, such as, for example, but in a non-limiting way, in the form of an optionally gelled aqueous solution, of a dispersion of the type lotion, of an O/W emulsion or vice versa W/O, more or less fluid, or of a multiple emulsion such as for example a triple emulsion (W/O/W or O/W/O), or even under the form of a vesicular dispersion of the ionic (liposomes) and/or non-ionic type, of a two-phase composition devoid of emulsifiers and gelling agents whose immiscible phases separate during storage, of foam, of stick, of anhydrous oil, spray or mist. In a preferred embodiment, the composition according to the invention is a W/O emulsion. In one particular embodiment, the W/O emulsions according to the invention comprise PEG-30 dipolyhydroxystearate (INCI), or polyglyceryl-4 diisostearate/polyhydroxystearate/sebacate as emulsifiers. These raw materials are respectively available from CRODA under the trade name of Cithrol DPHS and from EVONIK under the name of Isolan GPS. In an alternative embodiment, the composition according to the invention is an O/W emulsion. In a particular embodiment, the O/W emulsions according to the invention comprise an emulsifier chosen from the following group of compounds identified by their INCI designation: sodium stearoyl glutamate, potassium cetyl phosphate, glyceryl stearate/PEG-100 stearate and C20- 22 alkyl phosphate/C20-C22 alkyl alcohols, tribehenin PEG-20 esters, C14-C22 alcohols/ C12-20 alkyl glucoside, cetearyl alcohol/coco-glucoside, polyglyceryl-6 stearate, polyglyceryl-6 behenate and mixtures thereof. These raw materials are available from several suppliers. By way of example, the raw materials EMULGIN SG (INCI: sodium stearoyl glutamate; supplier: BASF); EMULIUM 22 (INCI: tribehenin PEG-20 esters; supplier GATTEFOSSE); SENSANOV WR (INCI: C20-22 alkyl phosphate/C20-C22 alkyl alcohols; supplier: SEPPIC); MONTANOV L (INCI: C14-C22 alcohols/ C12-20 alkyl glucoside), AMPHISOL K (INCI: potassium cetyl phosphate; supplier: DSM), MONTANOV 82 (INCI: cetearyl alcohol/coco-glucoside; supplier: SEPPIC) TEGO™ Care PBS 6 MB (INCI: polyglyceryl-6 stearate & polyglyceryl-6 behenate; supplier : EVONIK) can be used in the compositions according to the invention. According to another aspect, the invention relates to a composition as described above for its use for protection against ultraviolet solar radiation, in particular of wavelength between 100 and 400 nm. According to a particular embodiment, the invention relates to a composition comprising: at least one MAA as defined above, in particular chosen from the group consisting of the molecules corresponding to the INCI designations methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as possibly the compound corresponding to CAS number 2699128-33-9; -at least one UVB organic filter or a broad-spectrum organic filter absorbing in both UVB and UVA; at least one UVA organic filter; for its use to protect the skin, the mucous membranes and/or the appendages against UV radiation. According to a particular embodiment, the composition according to the invention is used to filter UV radiation between 280 and 400 nm, in particular between 300 and 380 nm. According to a particular embodiment, the invention relates to a composition comprising: - at least one MAA as defined above, in particular chosen from the group consisting of the molecules corresponding to the INCI designations methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as possibly the compound corresponding to CAS number 2699128-33-9; - at least two organic filters chosen from UVB organic filters and/or broad-spectrum organic filters absorbing both UVB and UVA rays; -at least one organic UVA screening agent, for its use as UV filtering agent, in particular for the wavelength spectrum comprised between between 280 and 400 nm, in particular between 300 and 380 nm. According to a particular embodiment, the invention relates to the use: - of at least one MAA as defined above, in particular chosen from the group consisting of the corresponding to the INCI designations methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as possibly the compound corresponding to CAS number 2699128-33-9; - at least two organic filters chosen from organic UVB filters and/or broad-spectrum organic filters absorbing both UVB and UVA rays; with -at least one UVA organic filter; for its use for the preparation of a cosmetic composition. The invention also relates to a cosmetic treatment process consisting in applying to the skin and to the appendages a composition comprising: at least one MAA as defined above, in particular chosen from the group consisting of the molecules corresponding to the INCI designations methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as optionally the compound corresponding to CAS number 2699128-33-9; - at least two organic filters chosen from organic UVB filters and/or broad-spectrum organic filters absorbing both UVB and UVA rays; -at least one organic UVA filter. The manner in which the invention can be implemented and the resulting advantages will emerge more clearly from the examples of embodiment which follow, given by way of indication and not limitation. Examples of embodiments of the invention The percentages indicated are given by mass of product relative to the total mass of the composition in the tables below. Example I – Sun emulsion [Table 1]

Example II – Sun emulsion [Table 2] Example III – Sun emulsion [Table 3] Example IV – Sun emulsion [Table 4]

Example V- Measurement of the sun protection factor (SPF) obtained with compositions according to the invention V-1 Aim of the study The aim of the study was the development of compositions with a so-called high sun protection factor SPF , that is to say with an SPF>20, incorporating organic UV filters and the MAAs according to the invention. V-2 Materials and methods An in vitro method for measuring the sun protection factor was used. A first measurement of UV absorption is carried out on a plate (plate molded in PMMA or sandblasted plate SB6, Helioscreen) covered with 15 μl of glycerine (white), this thus makes it possible to overcome the absorption of the support. For the fle1 and fle 2 formulas, the measurements were carried out using HD6 molded plates, according to the following protocol. Then, the product studied is sampled and deposited in 16 spots on the HD6 molded plate in PMMA from Helioscreen (5*5cm). The quantity weighed is 32.5 mg, which corresponds to a concentration of 1.3 mg/cm². The sample is spread uniformly using a spreader robot (HD-SPREADMASTER-Helioscreen). The plate is then placed in the dark at room temperature for at least 15 min. The plate is introduced into the measurement enclosure of the Labsphere UV 2000 S spectrophotometer, to perform UV absorption measurements between 290 and 400 nm. Note that a measurement actually corresponds to the average of 9 measurements (9 points of the PMMA plate are measured). In the cases of formulas fle 3 to fle 7, the protocol is identical but SB6 sandblasted plates were used. For these plates, the quantity weighed is 30 mg, which corresponds to a concentration of 1.2 mg/cm². Theoretical SPFs have been calculated for the individual filters, as under these conditions the in vitro SPF cannot be measured. The BASF simulator was used for these measurements (Herzog et al. 2003). The following formulas have been produced and tested: [Table 5]

Table 4: Comparative Formulas Containing Broad Spectrum and UVA Filters [Table 6] Table 6: Comparative formulas containing UVB and UVA IV-3 filters Results and discussion The SPF (sun protection factor) conferred by the different filters was measured: [Table 7] Table 7: SPF measurements of fle 1 and fle 2 [Table 8] Table 8: SPF measurements from fle 3 to fle 7 In the case of the tests relating to broad spectrum filters + UVA filter, a very low SPF was obtained for formula 1 (fle 1) containing an MAA according to the invention (INCI: methoxyphenylimino dimethylcyclohexene glycine), a UVA filter and a broad spectrum filter. The addition of a second broad spectrum filter made it possible to go from an SPF value of 5 to an SPF value of 21, whereas the expected theoretical contribution for the broad spectrum filter was 7.5. For the tests relating to UVB + UVA filters, the addition of a UVB filter in formula 4, containing an MAA according to the invention (INCI: methoxyphenylimino dimethylcyclohexene glycine), makes it possible to go from an SPF value of 12, 5 at an SPF value of 24.11. The addition of the same filter in the same concentration in formula 6, containing another MAA according to the invention (INCI: methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid) makes it possible to go from an SPF value of 11.73 to an SPF value of 25.93. The expected theoretical contribution for the 9% homosalate UVB filter was 4.6. The comparison between tests 3 and 5, which differ only by the presence of an MAA according to the invention, validates the sun protection amplifier function of the MAAs (SPF 18.62->24.11). In conclusion, with an equal protection index, the combinations of filters and MAA according to the invention make it possible to obtain products characterized by a good protection index (SPF > 20), while limiting the introduction of organic filters into the formulas thanks to the sun protection amplifier action of MAAs. Thus, the present invention makes it possible to reduce the quantity and concentration of organic screening agents required in a sunscreen product, while maintaining a high sun protection factor, that is to say greater than 20. The use of MAAs as anti-UV agent, in combination with organic filters, is an eco-compatible solution, eco-responsible for the environment and safe for humans. Bibliographic references Axelstad M., Boberg J., Hougaard KS, Christiansen S., Jacobsen PR, Mandrup KR, Nellemann C., Lund SP, Hass U. Effects of pre- and postnatal exposure to the UV-filter octyl methoxycinnamate (OMC) on the reproductive, auditory and neurological development of rat offspring. Toxicol. Appl. Pharmacol.250:278–90 (2011). Danovaro R., Bongiorni L., Corinaldesi C., Giovannelli D., Damiani E., Astolfi P., Greci L. Pusceddu A. (2008) Sunscreens cause coral bleaching by promoting viral infections. Environ Health Perspective 116(4):441-447. Herzog, B., Mendrok, C. & Mongiat, S., Müller, S, Osterwalder, U. (2003). The Sunscreen Simulator: A Formulator's Tool to Predict SPF and UVA Parameters. SOFW Journal.129: 25. Kinnberg KL, Petersen GI, Albrektsen M., Minghlani M., Awad SM, Holbech BF, Green JW, Bjerregaard P., Holbech H.. Endocrine-disrupting effect of the ultraviolet filter benzophenone-3 in zebrafish, Danio rerio. Around. Toxicol. Chem.34:2833–40 (2015). Ozáez, I., Morcillo, G., Martínez-Guitarte, JL Ultraviolet filters differentially impact the expression of key endocrine and stress genes in embryos and larvae of Chironomus riparius. Science. Total Approx.557-558: 240–247 (2016). Petersen, G., Rasmussen, D., Gustavson, K. Study on enhancing the Endocrine Disrupter priority list with a focus on low production volume chemicals Study on enhancing the Endocrine. Revised report to European Commission / DG Environment (2007). Rehfeld A., et al. Organic Ultraviolet Filters Mimic the Action of Progesterone on Human Sperm and Interfere with Sperm Functions. FRI 105-133-Endocrine Disrupting Chemicals and Gene Regulation and Development (posters) (2016). Schlumpf M., Cotton B., Conscience M., Haller V., Steinmann B., Lichtensteiger W. In vitro and in vivo estrogenicity of UV screens. Around. Health Perspective.109: 239–44 (2001). Schlumpf M., Durrer S., Faass O., Ehnes C., Fuetsch M., Gaille C., Henseler M., Hofkamp L., Maerkel K., Reolon S., Timms B., Tresguerres JA, Lichtensteiger W. Developmental toxicity of UV filters and environmental exposure: a review. Int J Androl.31:144-51 (2008). Szwarcfarb B., Carbone S., Reynoso R., Bollero G., Ponzo O., Moguilevsky J., Scacchi P. Octyl- Methoxycinnamate (OMC), an Ultraviolet (UV) Filter, Alters LHRH and Amino Acid Neurotransmitters Release from Hypothalamus of Immature Rats. Exp. Clin. Endocrinol. Diabetes 116: 94–98 (2008). Zucchi, S., Blüthgen, N., Ieronimo, A., Fent, K. The UV-absorber benzophenone-4 alters transcripts of genes involved in hormonal pathways in zebrafish (Danio rerio) eleuthero-embryos and adult males. Toxicol. Appl. Pharmacol.250:137–46 (2011).

Claims

Claims 1. Composition comprising: at least one amino acid analogue of mycosporin called "MAA" chosen from the group consisting of the molecules A of formula IA or one of its acceptable salts and/or the group consisting of the molecules B of formula IB or an acceptable salt thereof, said formula IA being: said formula IB being: for each of formulas IA and IB, - R1 is hydrogen; alkyl; alkenyl; alkynyl; aryl; heterocycle; cycloalkyl; alkoxy; alkanoyl; hydroxyl; a sulfo group; a halogen group; a phosphono group; an ester group; a carboxylic acid group; a phenyl group; an amino group; an alkylated fatty acid chain or a polyether; - R2 is alkyl; alkenyl; alkynyl; aryl; heterocycle; cycloalkyl; alkoxy; alkanoyl; a sulfo group; a phosphono group; an ester group; a carboxylic acid group; hydroxyl; or a phenyl group, characterized in that it further comprises: at least two organic screening agents chosen from organic UVB screening agents and/or broad-spectrum organic screening agents absorbing both in UVB and UVA; -at least one organic UVA filter.

2. Composition according to claim 1, characterized in that R1 is an alkoxy group of the type [CH3]-[CH2]n-O-, where "n" is between 0 and 10, preferably "n" 0 or "n" = 8.

3. Composition according to any one of the preceding claims, characterized in that R2 is a carboxylic acid group of the [COOH]-[CH ₂ ] _n - type, where “n” is between 0 and 5, preferably “n”= 1 or “n”=0.

4. Composition according to any one of the preceding claims, characterized in that said at least one MAA is chosen from the group comprising the following INCI designations: methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate , as well as the compound corresponding to CAS number 2699128-33-9.

5. Composition according to any one of the preceding claims, characterized in that the said at least one organic UVA filter is chosen from the group comprising the compounds corresponding to the following INCI designations: butyl methoxydibenzoylmethane, diethylamino hydroxybenzoyl hexyl benzoate, bis-(diethylaminohydroxybenzoyl benzoyl ) piperazine, disodium phenyl dibenzimidazole tetrasulfonate, especially butyl methoxydibenzoylmethane and diethylamino hydroxybenzoyl hexyl benzoate.

6. Composition according to any one of the preceding claims, characterized in that the said at least one organic UVB filter is chosen from the group comprising the compounds corresponding to the following INCI designations: ethylhexyl salicylate, homosalate, phenylbenzimidazole sulfonic acid and ethylhexyl triazone.

7. Composition according to any one of the preceding claims, characterized in that said at least one broad-spectrum organic screening agent is chosen from the group comprising bis ethylhexyloxyphenol methoxyphenyl triazine, diethylhexyl butamido triazone, tris-biphenyl triazine, phenylene bis-diphenyltriazine , methylene bis-benzotriazolyl tetramethylbutylphenol and drometrizole trisiloxane, in particular bis ethylhexyloxyphenol methoxyphenyl triazine, diethylhexyl butamido triazone, tris-biphenyl triazine, methylene bis-benzotriazolyl tetramethylbutylphenol.

8. Composition according to any one of the preceding claims, characterized in that the said at least one MAA represents between 0.1% and 20% by mass relative to the total mass of the composition, preferably between 0.5% and 10%, even more advantageously between 1 and 2%.

9. Composition according to any one of the preceding claims, characterized in that the said at least one organic UVB filter represents between 1% and 20% by mass relative to the total mass of the composition, preferably between 2% and 15% .

10. Composition according to any one of the preceding claims, characterized in that the said at least one organic UVA filter represents between 1% and 10% by mass relative to the total mass of the composition, preferably between 2% and 7% .

11. Composition according to any one of the preceding claims, characterized in that the said at least one broad-spectrum organic filter absorbing both in UVB and UVA represents between 1% and 15% by mass relative to the total mass. of the composition, preferably between 2% and 10%.

12. Composition according to any one of the preceding claims, characterized in that it comprises: at least two organic UVB screening agents; -at least one organic UVA filter.

13. Composition according to any one of the preceding claims, characterized in that it comprises: at least two broad-spectrum organic screening agents absorbing both in UVB and UVA rays; -at least one organic UVA filter.

14. Composition according to any one of the preceding claims, characterized in that it comprises: at least the UVB filters corresponding to the following INCI designations: octyl salicylate and homosalate; - at least the UVA organic filter corresponding to the following INCI designation: butyl methoxydibenzoylmethane.

15. Composition according to any one of the preceding claims, characterized in that it comprises: - at least the broad-spectrum filters absorbing both in UVB and UVA rays corresponding to the following INCI designations: diethylhexyl butamido triazone and bis- ethylhexyloxyphenol methoxyphenyl triazine; -at least one UVA sunscreen chosen from the group comprising the compounds corresponding to the following INCI designations: butyl methoxydibenzoylmethane, diethylamino hydroxybenzoyl hexyl benzoate, bis-(diethylaminohydroxybenzoyl benzoyl) piperazine, disodium phenyl dibenzimidazole tetrasulfonate, in particular butyl methoxydibenzoylmethane and diethylamino hydroxybenzoyl hexyl benzoate, advantageously butyl methoxydibenzoylmethane and diethylamino hydroxybenzoyl hexyl benzoate.

16. Composition according to any one of the preceding claims, characterized in that it is free of sunscreens corresponding to the following INCI designations: 4- methylbenzylidene camphor, 3-methylbenzylidene camphor, benzophenone-2, benzophenone-3, benzophenone-4 , ethylhexyl methoxycinnamate, isoamyl methoxycinnamate, octocrylene, octyl dimethyl PABA.

17. Composition according to any one of the preceding claims, characterized in that it has a so-called "SPF" sun protection factor equal to or greater than 20, advantageously equal to or greater than 30, preferably equal to or greater than 40, or even equal to or greater than 50.

18. Composition according to any one of the preceding claims, for its use for protection against solar radiation, in particular at wavelengths between 100 and 400 nm.